| First Author | Han Y | Year | 2019 |
| Journal | Cell Rep | Volume | 27 |
| Issue | 3 | Pages | 835-846.e5 |
| PubMed ID | 30995480 | Mgi Jnum | J:289763 |
| Mgi Id | MGI:6431895 | Doi | 10.1016/j.celrep.2019.03.082 |
| Citation | Han Y, et al. (2019) IL-38 Ameliorates Skin Inflammation and Limits IL-17 Production from gammadelta T Cells. Cell Rep 27(3):835-846.e5 |
| abstractText | Interleukin-38 (IL-38) is a cytokine of the IL-1 family with a role in chronic inflammation. However, its main cellular targets and receptors remain obscure. IL-38 is highly expressed in the skin and downregulated in psoriasis patients. We report an investigation in cellular targets of IL-38 during the progression of imiquimod-induced psoriasis. In this model, IL-38 knockout (IL-38 KO) mice show delayed disease resolution with exacerbated IL-17-mediated inflammation, which is reversed by the administration of mature IL-38 or gammadelta T cell-receptor-blocking antibodies. Mechanistically, X-linked IL-1 receptor accessory protein-like 1 (IL1RAPL1) is upregulated upon gammadelta T cell activation to feedforward-amplify IL-17 production and is required for IL-38 to suppress gammadelta T cell IL-17 production. Accordingly, psoriatic IL1RAPL1 KO mice show reduced inflammation and IL-17 production by gammadelta T cells. Our findings indicate a role for IL-38 in the regulation of gammadelta T cell activation through IL1RAPL1, with consequences for auto-inflammatory disease. |
